View Clinical Trial (Medical Research Study)

A Phase II Study of Single-Agent Lenalidomide in Subjects With Relapsed Or Refractory T-Cell Non-Hodgkin's Lymphoma - NCT00655668-90211(Clinical Trial 213356)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup
City:  Beverly Hills
State:  
CA
Zip Code: 90211
Conditions: Relapsed or Refractory T-Cell Non-Hodgkin's Lymphoma
Purpose: This is a Phase II, multicenter, single-arm, open-label study of oral lenalidomide monotherapy administered to subjects with relapsed or refractory T-cell lymphoma. This study will be conducted in two phases: a Treatment Phase and a Follow-up Phase. Subjects who qualify for enrollment into the study will enter the Treatment Phase and receive single-agent lenalidomide 25 mg once daily on Days 1-21 every 28 days (28-day cycles). Subjects may continue participation in the Treatment Phase of the study for a maximum duration of 24 months, or until disease progression or unacceptable AEs develop. All subjects who discontinue the Treatment Phase for any reason will continue to be followed until progression of disease or until next lymphoma treatment is given, whichever comes first, during the Follow-up Phase. Objectives: Primary: • To determine the efficacy of lenalidomide monotherapy in relapsed or refractory T-cell NHL. Efficacy will be assessed by measuring the response rate, tumor control rate, duration of response, time to progression and progression free survival. Secondary: • To evaluate the safety of lenalidomide monotherapy as treatment for subjects with relapsed or refractory T-cell NHL.
Study summary:
Criteria: Inclusion Criteria: - Must understand and voluntarily sign an informed consent form. - Must be ≥ 18 years of age at the time of signing the informed consent form. - Must be able to adhere to the study visit schedule and other protocol requirements. - Biopsy-proven T-cell non-Hodgkin's lymphoma, either: - PTCL whatever the subtype, or - CTCL, but only the subtype mycosis fungoides. - Relapsed or refractory to previous therapy for T-cell NHL. - Must have received at least one prior combination chemotherapy regimen. There is no limit on the number of prior therapies. Exclusion Criteria: - CTCL of subtype Sézary syndrome.
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.
Data Source: ClinicalTrials.gov
Date Processed: October 22, 2010
Modifications to
this listing:		 Only selected fields are shown, please use the link above to view all information about this clinical trial.